Siegrist Hans, Spieler Anja, Peters Andreas S, Passek Karola H, Böckler Dittmar, Dihlmann Susanne
Klinik für Gefäßchirurgie und Endovaskuläre Chirurgie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Vaskuläre Biomaterialbank Heidelberg (VBBH), Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
Biomolecules. 2024 Nov 28;14(12):1525. doi: 10.3390/biom14121525.
There is currently no clinically valid biomarker for predicting the growth and prognosis of abdominal aortic aneurysms (AAA). The most promising candidates with the highest diagnostic values are plasma D-dimers and markers of activated neutrophils, i.e., myeloperoxidase (MPO) or cell-free DNA. So far, case-control studies on these markers have been performed almost exclusively using healthy individuals as controls. To validate the value of these markers in the clinical setting of a vascular surgery department, we analysed the diagnostic and prognostic potential of plasma D-dimers and MPO in 177 AAA patients versus 138 non-AAA patients with different vascular diseases. Significantly elevated levels of D-dimers were recorded for AAA patients compared with non-AAA patients, although the difference between the two groups was significantly smaller than that in other studies comparing AAA patients with healthy controls. Surprisingly, MPO levels were significantly higher in non-AAA patients than in those with AAA. After adjusting for the confounding factors of sex, peripheral artery disease (PAD) and internal carotid stenosis in multivariate regression models, neither D-dimers nor MPO remained independent correlates of AAA. In contrast, D-dimer plasma levels correlated well with the maximal aortic diameter. Combined analysis of D-dimers and circulating cell-free DNA levels derived from a previous study failed to improve the predictive values for the maximal aortic diameter. In conclusion, our data show that D-dimers and MPO are not suitable biomarkers for monitoring AAA in a real-world setting of mixed vascular surgery patients.
目前尚无用于预测腹主动脉瘤(AAA)生长和预后的临床有效生物标志物。具有最高诊断价值的最有前景的候选物是血浆D-二聚体和活化中性粒细胞的标志物,即髓过氧化物酶(MPO)或游离DNA。到目前为止,关于这些标志物的病例对照研究几乎完全以健康个体作为对照。为了验证这些标志物在血管外科临床环境中的价值,我们分析了177例AAA患者与138例患有不同血管疾病的非AAA患者血浆D-二聚体和MPO的诊断和预后潜力。与非AAA患者相比,AAA患者的D-二聚体水平显著升高,尽管两组之间的差异明显小于其他将AAA患者与健康对照进行比较的研究。令人惊讶的是,非AAA患者的MPO水平显著高于AAA患者。在多变量回归模型中调整性别、外周动脉疾病(PAD)和颈内动脉狭窄等混杂因素后,D-二聚体和MPO均不再是AAA的独立相关因素。相比之下,D-二聚体血浆水平与主动脉最大直径密切相关。对来自先前研究的D-二聚体和循环游离DNA水平进行联合分析未能提高对主动脉最大直径的预测价值。总之,我们的数据表明,在混合血管外科患者的实际临床环境中,D-二聚体和MPO不是监测AAA的合适生物标志物。